Abstract
Mavodelpar, a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist, improves cellular bioenergetics in fibroblasts from patients with primary mitochondrial myopathy and complex I defiency
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
